| Name | Rituximab |
| Description | Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers. |
| Cell Research | Objective: Complement-mediated cell lysis. Concentrations: 0, 0.02, 0.2, 2, 20 μg/mL. Incubation Time: 2 h. Method: Lymphoma B cells were purified from lymph node biopsies of patients with B-cell lymphoma. Rituximab was added to tumor cells (1×106 /mL) in complete medium supplemented by human serum, inactivated or not by incubation at 56°C for 30 minutes. After 2 hours at 37°C, cell lysis was determined by PI staining of cells and analysis by flow cytometry. |
| In vitro | METHODS: B cells were treated with 0, 2.5, 5 and 10 μg/mL Rituximab to observe the effect of Rituximab on B cell proliferation.
RESULTS There was an optimal inhibition of B cell proliferation at a concentration of 5 μg/mL. [1] |
| In vivo | METHODS: 100 mg of Rituximab was administered over 4 h. Rituximab was then infused in a regimen of 3 weekly infusions for 4 weeks, and caspase-3 and PARP expression and protein hydrolysis processes were examined in patients.
RESULTS Rituximab induced cleavage of caspase-3, followed by the appearance of a 17-kd cleavage product corresponding to the large subunit of the catalytically active protease, and cleavage of PARP, a known substrate of cysteine asparaginase, was also detected. [2] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Rituximab | FcR |
| Inhibitors Related | Benzyl cinnamate | (9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one | Pirazolac | Sodium Iodoacetate | Teneligliptin hydrobromide | Soquelitinib | Difenpiramide | Anti-inflammatory agent 36 | Piperacetazine | MG-T-19 | Anti-inflammatory agent 35 | Complete Freund's adjuvant |
United States
